NASDAQ:FLKS
Delisted
Flex Pharma Stock News
$1.08
+0.340 (+45.95%)
At Close: Dec 03, 2020
BOSTON & HOUSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ: FLKS), and Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced th
Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018
03:19pm, Wednesday, 25'th Apr 2018
BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with sev
Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple Sclerosis
07:00am, Monday, 26'th Mar 2018
BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps, spasms and spasticity associated w
Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018
04:00pm, Wednesday, 28'th Feb 2018
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity asso
Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017
08:30am, Thursday, 02'nd Nov 2017
BOSTON--(BUSINESS WIRE)--Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spast
Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017
08:00am, Wednesday, 26'th Jul 2017
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity asso
Flex Pharma Reports First Quarter 2017 Financial Results
07:15am, Wednesday, 03'rd May 2017
BOSTON--(BUSINESS WIRE)--Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated wi
Flex Pharma to Report Fourth Quarter and Full Year 2016 Results on March 8, 2017
03:36pm, Wednesday, 01'st Mar 2017
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with the sev
Flex Pharma to Report Third Quarter 2016 Results on November 2, 2016
09:00am, Wednesday, 26'th Oct 2016
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), cramps and spasms ass
Flex Pharma Provides FLX-787 Nocturnal Leg Cramp Regulatory and Clinical Update
06:30am, Thursday, 13'th Oct 2016
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today provided a nocturnal leg cramp (NLC) regulatory and clinical update for FLX-787, a topically-acting, selective transient
Flex Pharma to Report Second Quarter 2016 Results on August 3, 2016
08:30am, Wednesday, 27'th Jul 2016
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), cramps and spasms ass
Flex Pharma to Report First Quarter 2016 Results on May 4, 2016
08:00am, Wednesday, 27'th Apr 2016
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated wit
Flex Pharma to Report Full Year 2015 Results on March 8, 2016
08:00am, Tuesday, 01'st Mar 2016
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated wit
Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study
07:00am, Tuesday, 02'nd Feb 2016
BOSTON--(BUSINESS WIRE)--Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated wit
Flex Pharma to Report Third Quarter 2015 Results on November 4, 2015
08:00am, Wednesday, 28'th Oct 2015
BOSTON--(BUSINESS WIRE)--Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cram
